Indus Biotech is a consumer healthcare products research company headquartered in Pune, India. It was founded in 1997 and focuses on identifying and developing a new generation of consumer healthcare products for Autoimmune, CNS, Infectious and Lifestyle diseases. Indus Biotech presently has clinically tested and marketed products in exercise physiology and an impressive pipeline of innovative products that are ready-to-launch. Indus Biotech has an innovative discovery and development paradigm that generates safe and efficacious products from food-chain raw materials that can effectively address the continuum of consumer healthcare spanning preservation of health, performance enhancement, risk reduction for disease susceptibility and therapeutics. Indus Biotech implements a unique business model that facilitates short-term revenue generation, while enabling long-term value creation. Vision & Values We endeavor to lead in creating safe and efficacious consumer healthcare products. We accomplish this through our innovative translational product discovery and development paradigm for: Preservation of health; Performance enhancement; Risk mitigation for disease; and Therapeutics. Discovery Model Conventional drug discovery model - high-cost, high-risk and uncertain The cost of drug discovery has ballooned to $1.3 billion[1]. The number of approvals of new drugs has significantly reduced. Nearly 43% of drug candidates fail due to efficacy problems, 33% due to safety concerns, and 11% due to pharmacokinetic issues during development [2]. Further, approved and marketed drugs are being withdrawn due to concerns regarding long-term safety, with 94% of such withdrawals due to toxicity[2]. Regulatory agencies are also seeking longer clinical studies in larger populations due to increased safety concerns. This has escalated the cost of drug discovery, driving the focus of Research & Development (R&D) primarily on "billion dollar" indications. Recovery of drug discovery investments today is only from highly priced and insurance reimbursed regulated markets such as USA, EU and Japan, which contribute as much as 80% of the market value [3]. Rest of the world (ROW) with 85% of the population represents only 20% of the market. This market bias defeats equitable and inclusive drug discovery. Indications like Malaria, Dengue and Tuberculosis are neglected. A disruptive innovation model is required to change the existing drug discovery paradigm for addressing this inequity.